Navigation Links
New statistical algorithms for Monitoring Gene Expression on GeneChip® Probe Arrays


Affymetrix has designed new algorithms for monitoring GeneChip® expression data. These statistical algorithms, created in response to customer input, were designed to accommodate the typical distribution of data found in microarray experiments. The new statistical algorithms employ standard statistical techniques and are optimized to accommodate advancements in array and probe selection technology. They provide accurate, high-quality analysis for GeneChip® array data. This new, statistically based approach provides:

– Calculation of statistical significance for detection and change calls (p-values) and confidence limits for log ratio values (fold change).
– Easily tunable parameters that enable the user to vary the stringency of the analyses.
– Elimination of negative expression values observed with the empirical algorithms.
– Easily referenced standard statistical techniques.

This technical note reviews the design and testing for Affymetrix® new statistical algorithms and explores performance characteristics of the statistical algorithms versus the previous empirical algorithms.

Experimental Design: How the New Algorithms Were Selected and Optimized

To select components for the new algorithms and test for optimization, a “training” data set was required. To conduct this comprehensive testing, each transcript group was spiked into a labeled mixture of RNA from a tissue source in an experimental design known as a Latin Square. A Latin Square is used to accurately monitor the detectability of transcripts over a range of concentrations. It also allows the statistical analysis of patterns and variability in repeated measurements in a systematic fashion, thus revealing patterns in the data and allowing rigorous comparisons. The Latin Square experimental design used in the development of the statistical algorithms enabled thorough testing of a large set of transcripts over a broad range of concentrations. (Figure 1)

The Latin Square experimental design was used extensively in the algorithm development process to test a wide range of data sets, including transcript groups of E.coli, S. cerevisiae and H. sapiens . In the human Latin Square, each transcript group was designed to contain one distinct human transcript from 0 to 1024 pM in concentration. These were spiked into a labeled mixture of human RNA where these 14 transcripts showed no expression. In total, 12 transcripts were used to compute the results; two of the transcripts were removed from the final calculations due to low quality. In the yeast Latin Square, each transcript group contained eight different transcripts, labeled and spiked into a mixture of labeled human RNA. After hybridization to Human Genome U95Av2 or Yeast Genome S98 arrays respectively, Affymetrix® Microarray Suite (MAS) 4.0 containing the empirical algorithms and MAS 5.0 containing the new statistical algorithms were used to analyze the data.

In addition to Latin Square experiments, more conventional data sets were generated and analyzed where RNA from different sources was labeled and hybridized to GeneChip® probe arrays, followed by analysis with MAS 4.0 and MAS 5.0.


Comparison of Expression Values Generated by MAS 4.0 and MAS 5.0

Analyses were performed to study the concordance between expression values generated by empirical algorithms (MAS 4.0) and statistical algorithms (MAS 5.0). Experiments performed with human adrenal gland RNA on human genome U95A arrays are shown in Figure 2.

As shown in Figure 2A, when results generated with MAS 4.0 and MAS 5.0 are compared, the results are highly similar, with a regression ratio of 0.94. Similar results were obtained across multiple tissues and with replicates (data not shown). This similarity was also observed on arrays representing different organisms. The regression ratios for these comparisons were in the 0.92-0.93 range for M. musculus, A. thaliana and S. cerevisiae , and 0.96-0.97 for D. melanogaster and E. coli .

The occurrence of negative values in MAS 4.0, seen in the two left quadrants in Figure 2B, has been eliminated from MAS 5.0. The corresponding output in MAS 5.0, termed “Signal” has no negative and zero values as is evident in the lower two quadrants of Figure 2B.

Added Statistical Quality Measures and Tunable Parameters

An added benefit of the statistical algorithms in MAS 5.0 is the inclusion of probability values (statistical significance) associated with detection and comparison calls. This additional metric allows users to assess the significance of results, and if desired, adjust the balance between sensitivity and specificity. For example, higher confidence in expression calls (greater specificity) can be achieved by accepting fewer Present calls (lower sensitivity). Conversely, greater sensitivity may be achieved at the expense of lower specificity. The inverse relationship between sensitivity and specificity in MAS 5.0 was examined by monitoring detection calls in the set of experiments described below. As shown in Figure 3, a greater number of accurate Present calls is made by MAS 5.0 at concentrations below 4 pM using the default p-value setting. However, the small number of false positives is also slightly greater for MAS 5.0 in this experiment, as seen at the 0 pM concentration. The sensitivity and specificity may be varied in a predictable fashion by varying the default setting for p-value cutoff.

Figure 4 illustrates the linearity of dose response from the 14 spiked transcripts and the upper and lower confidence limits. It also demonstrates that signal calculation in the statistical algorithms (MAS 5.0) generates signal values that accurately reflect the true concentration.

As with Figure 2, no signal value in Figure 4 is ever negative or zero. This allows signal values to be easily transformed to a logarithmic scale.

The effects of altering tunable confidence parameters on Present calls were studied in a yeast Latin Square experiment. The tunable parameter controlling the number of Present calls is termed a1 (alpha1). Altering a1 results in a shift in the p-value cutoff used to make a Present call.

This parameter was varied in this analysis to determine the effect on the number of Present calls at different concentrations.

Calls at higher concentrations are typically unaffected by altering a1. At concentrations below 8 pM in this experiment, a decrease in stringency (i.e., increase in a1 from 0.04 to 0.1) results in an increasing number of Present calls. As Figure 5 shows, a1 may be varied to obtain sensitivities using MAS 5.0 that are greater or lower than those obtained with MAS 4.0. However, an increase in a1 produces a corresponding increase in the number of false positive calls, as seen at the 0 pM concentration. It should be noted that false positives can easily be flagged by their high p-values.

Comparison Calls Generated by MAS 4.0 and MAS 5.0 Show Concordance

Analyses were performed to study the concordance between comparison calls generated by MAS 4.0 and MAS 5.0. To assess “No Change” calls, comparison analysis was performed on replicate Human Genome U95A arrays from the human Latin Square experiment, where transcript group concentrations were identical between experiments. Therefore, a No Change call is expected for each transcript group between replicates. Results are shown in Figure 6.

The results show that for both MAS 4.0 and MAS 5.0, over 95% (at some concentrations 100%) correct No Change calls are made.

The concordance between Increase calls made by MAS 4.0 and MAS 5.0 are shown in Figure 7. The same transcript group was compared in pairs of experiments to evaluate the calls for a 2-fold and 4-fold change in concentration. For example, in the Latin Square represented in Figure 1, transcript group B was compared between Experiments 1 and 2, then 2 and 3, then 3 and 4, and so on, to determine the fraction correctly assigned an Increase call at the expected 2-fold change. For the 4-fold change, transcript group B was compared between Experiments 1 and 3, 2 and 4, 3 and 5 etc., such that all transcript groups were evaluated.

In this data set, MAS 5.0 shows greater accuracy than does MAS 4.0 at both 2-fold and 4-fold Increase levels. For example, at the 2 pM spike in Figure 7B, MAS 5.0 gives a nearly 10% greater fraction of correct Increase calls than does MAS 4.0. The drop in accuracy seen at very high concentration is due to the saturation of probe sets by the vast excess of spiked transcripts.

To understand the difference in the performance of calls generated by MAS 4.0 and MAS 5.0 on a biological sample, we assessed the results using an independent method. We used the power of replicates and the wellknown student’s t-test as a reference.

We analyzed a number of replicates in two tissues and then asked, “How well do the results from any single comparison match results from the group as a whole?”

The group was built from two sets of experiments—mouse brain and mouse heart—containing six replicates for each tissue. Each replicate was compared to every other replicate with both MAS 4.0 and MAS 5.0 (36 comparisons of 12488 probe sets). The t-test was then used to evaluate whether the mean of the replicates in one tissue was significantly different from the mean of the replicates in the other tissue. The results are shown in Figure 8.

Overall, the Comparison calls generated by MAS 4.0 and MAS 5.0 are highly similar. The No Change calls of both MAS 4.0 and MAS 5.0 peak at approximately 0.9, as we would expect. The Decrease calls (D) peak at 1 and the Increase calls (I) peak towards zero for both algorithms, while the lines follow each other very closely. The additional benefit of MAS 5.0 is that we now have p-values to assess statistical significance of the comparisons of every gene.

The next technical note will contain more results on Comparison calls and their performance in MAS 5.0, together with discussions of tunable parameters and confidence limits.


In conclusion, our extensive validation studies, some results from which are shown above, allow us to state with confidence the following:

– The new statistical algorithms in MAS 5.0 perform as robustly and precisely as the previous algorithms, while providing the additional value of statistical significance (p values) and confidence limits, thereby offering GeneChip® users the ability to evaluate the significance of their results.

– Negative expression values (signals) have been eliminated; only positive values are generated in MAS 5.0.



Page: All 1 2 3 4 5 6

Related biology technology :

1. Versatile Reporter Vectors for Monitoring Viral Transduction
2. Monitoring transfection efficiency by green fluorescent protein (GFP) detection with the Agilent 2100 bioanalyzer
3. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
4. Monitoring Bacterial Genetic Diversity in a Freshwater Lake Using TTGE and DNA Sequence Analysis
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Monitoring fluorescence resonance energy transfer (FRET) between GFP fusions in lysates of the yeast Saccharomyces cerevisiae using the Varian Cary Eclipse
7. Monitoring Receptor-Mediated Changes in [Ca2+]i Using Single-Wavelength and Dual-Wavelength Indicators on the FlexStation Workstation
8. An Epitope Tagging Vector for Gene Expression in Mammalian Cells
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. High-Level Expression of Peanut Allergens Affected by Rare Codon Usage
11. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
Post Your Comments:

(Date:6/27/2017)... ... 27, 2017 , ... Biodex Medical Systems, Inc. announces the release of the ... assistive aid lifts patients safely from a seated to a standing position without staff ... Assist is the latest in a line of Biodex products promoting safe patient handling. ...
(Date:6/27/2017)... ... 2017 , ... Indiana-based Xylogenics announced today the release of ... The efficiencies created by the newest strain design will have an immediate ... wherein individual production plants are planning to invest upwards of $350 million annually ...
(Date:6/26/2017)... VIRGINIA (PRWEB) , ... June 26, 2017 , ... ... today that Melissa Kirkegaard, the former Associate Director of Product Development R&D at ... biological and pharmaceutical products at both start-up and established biopharma companies, has joined ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... The ... use of health IT to create efficiencies in healthcare information exchange and a statutory ... W. Rucker, MD, head of the federal Office of the National Coordinator for Health ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):